Single Dose Bronchodilatory Study in Asthma


Study to evaluate the bronchodilator effects of Zyflo CR in patients with chronic stable asthma.

Full Title of Study: “A Single-Center, Open-Label, Single-Dose Evaluation of the Duration and Extent of Bronchodilation Following Administration of Zileuton CR 1200 mg in Subjects With Stable, Chronic Asthma”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 2013


  • Drug: Zileuton extended release

Arms, Groups and Cohorts

  • Other: Zileuton extended release
    • Oral, 1200 mg (2 x 600 mg tablets)

Clinical Trial Outcome Measures

Primary Measures

  • Change From Baseline in FEV1
    • Time Frame: 12 Hours

Secondary Measures

  • Area Under the Curve (AUC)
    • Time Frame: 72 Hours
  • Number of Subjects With Adverse Events
    • Time Frame: 72 Hours

Participating in This Clinical Trial

Inclusion Criteria

  • Diagnosis of asthma for at least 5 years – FEV1 of 50-85% predicted – Reversible airway obstruction Exclusion Criteria:

  • Pregnant/nursing females – Liver function tests greater than upper limit of normal

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Cornerstone Therapeutics Inc.
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.